Switzer TV

 

Welcome back for another year of stock picks, top LICs and trading tips with Switzer Investing TV. Good to have you aboard.

On this kick-off ep for the new year, we're looking at roughed-up companies on the market that might be worth a second look. Quality stocks are being sold hard, resources are back in favour, and investors are asking the same uncomfortable question, is this a buying opportunity or a value trap?

In this first show of the year, Peter Switzer sits down with Adam Dawes from Shaw and Partners, Mike Gable from Fairmont Equities, and Paul Rickard from the Switzer Report to cut through the noise.

They run the ruler over some of the market’s most talked-about names, including CSL, NextDC, Xero, WiseTech, Pro Medicus, lithium plays, uranium stocks, and gold. Fundamentals meet charts, sentiment clashes with valuation, and the panel doesn’t always agree. You’ll hear why great businesses can fall a long way without anything being “wrong”, what the charts are really saying about beaten-up tech, why resources have momentum again, and whether gold is still a defensive play with upside in 2026.

Switzer Investing TV (19/12/25): Are these smashed stocks worth your time?

On this kick-off ep for the new year, we're looking at roughed-up companies on the market that might be worth a second look. Quality stocks are being sold hard, resources are back in favour, and investors are asking the same uncomfortable question, is this a buying opportunity or a value trap?

More videos

Mad about Money

Peter Switzer shares his thoughts on the major current affairs impacting financial markets and the economy.

Series:
Is mobile phone use associated with an increased risk for brain cancer? | The Check Up

There have always been rumours on whether mobile phones are really linked with an increased risk for brain cancer. In this week's episode, Dr Ross looks at certain studies to assess this claim.

Series:
Michael Wayne on these stocks & more; TYR, APX, DDR + What's going on in the housing market?

Peter Switzer is joined by Michael Wayne of Medallion Financial, ST Wong of Prime Value, and CEO of Rate Money, Ryan Gair.

Series:
Are we heading for a recession? + Expert analysis on these 7 stocks!

Peter Switzer is joined by Michael Gable of Fairmont Equities, and Marcus Bogdan of Blackmore Capital.

Series:
A promising male contraception pill with zero effects on hormones?! | The Check Up

Currently, the only form of male contraception is a condom and a vasectomy. However, through certain studies and research conducted with mice, we may soon see a contraception pill for males with no hormonal effects.

Series:
Mad about Money

3 reasons why Dr Phil better be careful about raising interest rates & could stocks slide tomorrow?

Series:
5 quality stocks; GMG, ANZ, XRO, JBH & S32 + Should we fear the fed interest rate decision?

Peter Switzer is joined by Jun Bei Liu of Tribeca Investment Partners, Anthony Doyle from Firetrail Investments and Paul Rickard is joined by Angus Moore from Proptrack.

Series:
What is immunotherapy and how does it fight cancer? | The Check Up

Dr Ross explains whether immunotherapy could be the new approach that could lead to an effective treatment for various types of cancer.

Series:
4 mid-cap stocks for your portfolio + How do you renovate or build and stay within your budget?

Paul Rickard is joined by Rudi Filapek-Vandyck of FNArena, Raymond Chan of Morgans, and Anna Porter from Suburbanite.

Series:
Mad about Money

US inflation disappoints & Wall Street tanks + Star Entertainment: 'Unfit to hold casino license'.

Series:
Why are copper, nickel and lithium stocks on the rise? + 3 growth companies; DGL, PPE & SMP

Paul Rickard is joined by Michael Wayne of Medallion Financial, Adam Dawes of Shaw and Partners, and Ron Shamgar of Tamim Asset Management.

Series:
Can a high dose of vitamin E really cause death? | The Check Up

Dr Ross has a look at whether a high dose of vitamin E can actually lead to death, as some studies show.

Series:
1 9 10 11 12 13 51

Fill in the form below to subscribe to Switzer Daily and get our latest articles, videos and podcasts sent straight to your inbox

Get the latest financial, business, and political expert commentary delivered to your inbox.

When you sign up, we will never give away or sell or barter or trade your email address.

And you can unsubscribe at any time!
Subscribe
© 2006-2021 Switzer. All Rights Reserved. Australian Financial Services Licence Number 286531. 
shopping-cartphoneenvelopedollargraduation-cap linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram